Dedicated to advancing healthcare, Cambridge-1 represents a $100 million investment by NVIDIA. Its first projects with AstraZeneca, GSK, Guy's and St Thomas' NHS Foundation Trust, King's College London and Oxford Nanopore Technologies include developing a deeper understanding of brain diseases like dementia, using AI to design new drugs and improving the accuracy of finding disease-causing variations in human genomes.
Cambridge-1 brings together decades of NVIDIA's work in accelerated computing, AI and life sciences, where NVIDIA Clara and AI frameworks are optimized to take advantage of the entire system for large-scale research. An NVIDIA DGX SuperPOD supercomputing cluster, it ranks among the world's top 50 fastest computers and is powered by 100 percent renewable energy.
Cambridge-1 builds on the U.K.'s status as a global leader in life sciences, technology and AI by providing advanced infrastructure for current and future generations to carry out groundbreaking research within the country. According to a report by Frontier Economics, an economics consulting firm, Cambridge-1 has the potential to create an estimated value of £600 million (about $825 million) over the next 10 years.
Cambridge-1 is the first NVIDIA supercomputer designed and built for external research access. The company will collaborate with researchers to make much of this work available to the greater scientific community.
Featuring 80 DGX A100 systems integrating NVIDIA A100 GPUs, BlueField -2 DPUs and NVIDIA HDR InfiniBand networking, Cambridge-1 is an NVIDIA DGX SuperPOD that delivers more than 400 petaflops of AI performance and 8 petaflops of Linpack performance. The system is located at a facility operated by NVIDIA partner Kao Data.
Cambridge-1 is the first supercomputer NVIDIA has dedicated to advancing industry-specific research in the U.K. The company also intends to build an AI Center for Excellence in Cambridge featuring a new Arm-based supercomputer, which will support more industries across the country.